Early clinical trials were encouraging [23, 24], but research was discontinued due to cross-reactivity of anti-TPO autoantibodies with endogenous TPO resulting in drug-induced thrombocytopenia [25]. The gene discussed is TPO; the disease is Thrombocytopenia.